Search Results
Year | ID | Type | Category | Title | Authors |
---|
2023 | CSR08 | Poster | Case Reports/Case Series |
Clinical Progression without Relapses in Myelin Oligodendrocyte Glycoprotein Antibody Positive Patients |
Aisha Elfasi, MD1, Elsa Rodriguez, MD1, Samir Alkabie, MD, MSc2, Garrett Timmons, MD3, Mayra Montalvo, MD1, Fernando X Cuascut, MD, MPH4, Rhaisa Castrodad, MD4, George J Hutton, MD4, Revere Kinkel, MD5, Jennifer Graves, MD, PhD, MAS6 and Torge Rempe, MD1, (1)Neurology, University of Florida, Gainesville, FL, (2)Western University, London, ON, Canada, (3)Stanford University School of Medicine, Stanford, CA, (4)Baylor College of Medicine, Houston, TX, (5)University of California San Diego, La Jolla, CA, (6)University of California San Diego, San Diego, CA |
2023 | CSR09 | Poster | Case Reports/Case Series |
Toddler-Onset Pediatric Multiple Sclerosis: A Case Report and Prospective Insights |
Rufaidah Rushdi, Master of Science in Pediatrics1, Nevin Shalaby, Professor of Neurology2 and Fawzia Mossad, Lecturer of Pediatric Neurology1, (1)Pediatrics, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt, (2)Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo, Egypt |
2023 | DMT07 | Poster | Disease-modifying therapy |
An Increase in Absolute Lymphocyte Count Following the Switch from Brand to Generic Dimethyl Fumarate |
Camila Ishueva, BS1, Michelle Maynard, PharmD, BCPS2 and Ahmed Z Obeidat, MD, PhD1, (1)Neurology, Medical College of Wisconsin, Milwaukee, WI, (2)Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI |
2023 | DMT08 | Poster | Disease-modifying therapy |
Treatment Convenience in Multiple Sclerosis: A Patient Preference Study |
Alexander Keenan, MS, MHP1, Chiara Whichello, PhD2, Matt Quaife, PhD2, David M. Kern, PhD3, Gabriela Fernandez, PhD4, Vicky Turner, PhD2, Hoa H. Le, PhD5 and Amy Perrin Ross, APN, MSN, CNRN, MSCN6, (1)Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, (2)Evidera, London, United Kingdom, (3)Janssen Research & Development, LLC, Titusville, NJ, (4)Evidera, Bethesda, MD, (5)Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ, (6)Loyola University Chicago, Chicago, IL |
2023 | DMT09 | Poster | Disease-modifying therapy |
Clinical Characteristics and Treatment Outcomes in MS Patients Treated with Anti-CD20s Who Switched to Fumarates |
Aliza B. Ben-Zacharia, PhD, DNP, ANP, FAAN1,2, Jenny Feng, MD3, Brandon Moss, MD4, Nick Belviso, PhD5, Yu Zhang, MSc5, Filipe Branco, MSc6, Jason P. Mendoza, PhD5, James B. Lewin, PharmD5 and Sarah M. England, PhD5, (1)Phillips School of Nursing at Mount Sinai, New York, NY, (2)Hunter College, New York, NY, (3)Ochsner Medical Center, New Orleans, LA, (4)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, (5)Biogen, Cambridge, MA, (6)Biogen, Baar, Switzerland |
2023 | DMT10 | Poster | Disease-modifying therapy |
Early Clinical Experience with Cladribine Tablets in a Black/Hispanic Population |
Amparo Gutierrez, MD FAAN FANA1, Deborah Chandler, ARNP DNP1 and Andreina Neall, ARNP2, (1)Neurology, Orlando Health, Orlando, FL, (2)Orlando Health, Orlando, FL |
2023 | DMT11 | Poster | Disease-modifying therapy |
No Difference in Serum Immunoglobulins Levels in Multiple Sclerosis Patients Switching from Infusible to Subcutaneous Anti-CD20 Therapy |
Amro Elrefaei, MD, Mokshal H Porwal, BSc and Ahmed Z Obeidat, MD, PhD, Neurology, Medical College of Wisconsin, Milwaukee, WI |
2023 | DMT12 | Poster | Disease-modifying therapy |
Recently Diagnosed Treatment-Naive RRMS: 4-Year Safety & Efficacy Data from the Ocrelizumab Phase IIIb ENSEMBLE Study |
Amy Perrin Ross, APN, MSN, CNRN, MSCN1, Thomas Berger, MD, MSc2, Robert A. Bermel, MD3, Mark S Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC4, Trygve Holmøy, MD, PhD5,6, Francesco Patti, MD, PhD7, Inessa Kulyk, MD, MBA8, Karen Kadner, MD, PhD8, Thomas Kuenzel, PhD8 and Hans-Peter Hartung, MD, FRCP, FEAN, FAAN, FANA9,10,11, (1)Loyola University Chicago, Chicago, IL, (2)Department of Neurology, Medical University of Vienna, Vienna, Austria, (3)Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, (4)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (5)Institute of Clinical Medicine, University of Oslo, Oslo, Norway, (6)Department of Neurology, Akershus University Hospital, Lørenskog, Norway, (7)Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, (8)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (9)Department of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, (10)Department of Neurology, Medical University Vienna, Vienna, Austria, (11)Brain and Mind Centre, University of Sydney, Sydney, Australia |
2023 | DMT13 | Poster | Disease-modifying therapy |
Safety of Shorter Ocrelizumab Infusion Confirmed over Multiple Administrations: Results of the ENSEMBLE PLUS Substudy |
Amy Perrin Ross, APN, MSN, CNRN, MSCN1, Joep Killestein, MD, PhD2, Thomas Berger, MD, MSc3, Robert A. Bermel, MD4, Bruno Brochet, MD5, William M Carroll, AO, AM, MBBS, MD, FRACP, FRCP6, Mark S Freedman, MSc, MD7, Trygve Holmøy, MD, PhD8,9, Rana Karabudak, Prof., MD10, Carlos Nos, MD11, Francesco Patti, MD, PhD12, Ludo Vanopdenbosch, MD13, Timothy Vollmer, PhD14, Regine Buffels, MD15, Karen Kadner, MD, PhD15, Oscar Bortolami, PhD15, Hans-Peter Hartung, MD, FRCP, FEAN, FAAN, FANA16,17,18,19 and on behalf of the ENSEMBLE Investigators and Steering Committee, (1)Loyola University Chicago, Chicago, IL, (2)Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands, (3)Department of Neurology, Medical University of Vienna, Vienna, Austria, (4)Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, (5)University of Bordeaux, Bordeaux, France, (6)Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, the University of Western Australia, Nedlands, Australia, (7)Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada, (8)Institute of Clinical Medicine, University of Oslo, Oslo, Norway, (9)Department of Neurology, Akershus University Hospital, Lørenskog, Norway, (10)Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, (11)Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, (12)Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, (13)Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, (14)Department of Neurology, University of Colorado School of Medicine, Aurora, CO, (15)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (16)Department of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, (17)Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic, (18)Research Centre for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland, (19)Brain and Mind Centre, University of Sydney, Sydney, Australia |
2023 | DMT14 | Poster | Disease-modifying therapy |
Evaluating Large Scale Proteomic Changes in Cerebrospinal Fluid (CSF) of Patients Living with Multiple Sclerosis (MS) and Treated with Tolebrutinib |
Anna S. Blazier, PhD1, Gregory Wirak, PhD1, Pavithra Krishnaswami, MSc1, Mikhail Levit, PhD1, Dimitry Ofengheim, PhD1, Timothy J. Turner, PhD1, Steven Jacobson, PhD2 and Daniel S. Reich, MD, PhD2, (1)Sanofi, Cambridge, MA, (2)National Institute of Neurological Disorders and Stroke, Bethesda, MD |
2023 | DMT15 | Poster | Disease-modifying therapy |
Budget Impact Analysis of Transitioning from Reference to Biosimilar Natalizumab from a United States Payer Perspective |
Edward Li, PharmD MS, HEOR, Sandoz Inc, Princeton, NJ, Adrian Goh, M.Econ, V&A-Economic modeling, Novartis Corporation Sdn Bhd, Selangor, Malaysia, Soni Gupta, M.Econ, V&A, Novartis Healthcare Pvt. Ltd, Hyderabad, India, Anna Chen, PharmD, MSc, Associate Director HEOR/RWE, Sandoz inc, Princeton, NJ, Marion Schauf, Dipl.-Kff., Franchise Launches Biopharma, Sandoz International GmbH, Holzkirchen, Germany and Daniel Hartung, PharmD, MPH, College of Pharmacy,, Oregon State University, Portland, OR |
2023 | DMT16 | Poster | Disease-modifying therapy |
Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Evobrutinib-Treated Patients with RMS: An Update |
Amit Bar-Or, MD1, Anne H. Cross, MD2, Anthony Cunningham, AO FAHMS3, Yann Hyvert, PhD4, Andrea Seitzinger, PhD4, Elise E. Drouin, PhD5, Nektaria Alexandri, MD, MSc6, Davorka Tomic, PhD7 and Xavier Montalban, MD PhD8, (1)Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (2)Washington University School of Medicine, St. Louis, MO, (3)The Westmead Institute for Medical Research, Director Centre for Virus Research, Sydney, Australia, (4)The healthcare business of Merck KGaA, Darmstadt, Germany, (5)EMD Serono, Billerica, MA, (6)The healthcare business of Merck KGaA,, Darmstadt, Germany, (7)Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, (8)Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain |
2023 | DMT17 | Poster | Disease-modifying therapy |
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease |
Anthony Krakovich, MD, MPH1, Giancarlo Comi, MD2, Marla C. Dubinsky, MD3, Uma Mahadevan, MD4, Lorna Charles, MD1, C. Janneke van der Woude, MD, PhD5 and Krzysztof W. Selmaj, MD, PhD, DSc6, (1)Bristol Myers Squibb, Princeton, NJ, (2)Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, (3)Icahn School of Medicine at Mount Sinai, New York, NY, (4)Gastroenterology Division, Department of Medicine, University of California San Francisco, San Francisco, CA, (5)Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands, (6)Center for Neurology, Lodz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland |
2023 | DMT18 | Poster | Disease-modifying therapy |
Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial |
Anthony Traboulsee, MD1, Robert J. Fox, MD2, Douglas L. Arnold, MD3, Sana Syed, MD, MPH4, Larry Orogun, MD, MSc4, Deborah Dukovic, MS5, Timothy J. Turner, PhD4, Daniel S. Reich, MD, PhD6 and Jiwon Oh, MD, PhD7, (1)University of British Columbia, Vancouver, BC, Canada, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (4)Sanofi, Cambridge, MA, (5)Sanofi, Bridgewater, NJ, (6)National Institute of Neurological Disorders and Stroke, Bethesda, MD, (7)St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada |
2023 | DMT19 | Poster | Disease-modifying therapy |
MRI Outcomes from the Long-Term Safety Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 2-Year Results |
Daniel S. Reich, MD, PhD1, Anthony Traboulsee, MD2, Sana Syed, MD, MPH3, Zhixing Xu, PhD4, Timothy J. Turner, PhD3 and Douglas L. Arnold, MD5,6, (1)National Institute of Neurological Disorders and Stroke, Bethesda, MD, (2)University of British Columbia, Vancouver, BC, Canada, (3)Sanofi, Cambridge, MA, (4)Sanofi, Bridgewater, NJ, (5)NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (6)NeuroRx Research, Montreal, QC, Canada |
2023 | DMT20 | Poster | Disease-modifying therapy |
A Review of Dmt Initiation, Change, and Discontinuation in a Real World Clinical Setting at Kootenai Clinic Center for Comprehensive MS Care. |
Autumn Ramsrud, PharmD, CSP, MSCS, Tyler Cress, PharmD, MSCS, Katherine Gwin, RN, BSN, MSCS, MSCN, Kaelianne Newbold, RN, BSN, MSCS, MSCN, Cindy Smith, PharmD, CSP, Angie Critchfield, CPhT and Nina Bozinov, MD, MS, Neurology, Kootenai Clinic, Coeur d’Alene, ID |
2023 | DMT21 | Poster | Disease-modifying therapy |
Long-Term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis |
Bruce A.C. Cree, MD1, Silvio Danese, MD2, Douglas C. Wolf, MD3, Olga Alekseeva, MD4, Lorna Charles, MD5, AnnKatrin Petersen, MD5, James K. Sheffield, MD MBA MSMD5, Chun-Yen Cheng, MS5, Jon V. Riolo, MD5, Diego Silva, MD5, Fred D. Lublin, MD6, David T. Rubin, MD7 and Jeffrey A. Cohen, MD8, (1)Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (2)Humanitas University, Milan, Italy, (3)Atlanta Gastroenterology Associates, LLC, Atlanta, GA, (4)Nizhegorodskaya Regional Clinical, Nizhegorodskaya oblast’, Russian Federation, (5)Bristol Myers Squibb, Princeton, NJ, (6)Mount Sinai Medical Center, New York, NY, (7)University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, (8)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH |
2023 | DMT22 | Poster | Disease-modifying therapy |
Toward the Provision of Equitable MS Care: How Continuing Medical Education (CME) Can Help Move the Needle |
Carole Drexel, PhD, PlatformQ Health Education, Needham, MA, Emily Bixler, MBA, PlatformQ Health, Needham, MA, Robert K Shin, MD, Georgetown University Medical Center, Washington, DC, Lilyana Amezcua, MD, MS, Keck School of Medicine, University of Southern California, Los Angeles, CA and June Halpert, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers, Hackensack, NJ |
2023 | DMT23 | Poster | Disease-modifying therapy |
Real-World Clinical and Economic Outcomes Among Persons with Multiple Sclerosis Initiating First Versus Second-Line Treatment with Ocrelizumab |
Caroline K Geiger, PhD, Daniel Sheinson, PhD, Tu My To, PhD, MPH, David E Jones, MD and Nicole G Bonine, PhD, MPH, Genentech, Inc., South San Francisco, CA |
2023 | DMT24 | Poster | Disease-modifying therapy |
Pregnancy and Infant Outcomes from an Ongoing Worldwide Surveillance Program of Cladribine Tablets: 5-Year Pharmacovigilance Results from Maple-MS |
Kerstin Hellwig, MD, Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany, Hugh H Tilson, MD, UNC Gillings School of Global Public Health, Chapel Hill, NC, Joerg Seebeck, MD, Global Patient Safety, Merck KGaA, Darmstadt, Germany, Aida Aydemir, MD, EMD Serono Research & Development Institute, Inc., Billerica, MA and Meritxell Sabidó, MD, PhD, Merck KGaA, Darmstadt, Germany |
2023 | DMT25 | Poster | Disease-modifying therapy |
Real-World Persistence and Adherence of Ofatumumab Versus Platform Self-Injectable Disease Modifying Therapies (DMTs) in Patients with Multiple Sclerosis (MS) |
Magdaliz Gorritz, MPH1, Chi-Chang Chen, PhD1, Rifat Tuly, MPH1, Yifan Gu, MS1, Qiujun Shao, PhD2, Abhijit Gadkari, PhD2, Brandon Brown, PharmD2 and Carrie M Hersh, DO, MS, FAAN3, (1)IQVIA, Plymouth Meeting, PA, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)Mellen Program for Multiple Sclerosis Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV |
2023 | DMT26 | Poster | Disease-modifying therapy |
Adherence to Disease-Modifying Treatments in Patients with Active and Nonactive Progressive Multiple Sclerosis in the United States |
Jiahe Chen, MS1,2, Crystal Watson, MS3, Dhanalakshmi Thirumulai, PhD, MPH1, Arie Barlev, PharmD, MS3, Eddie Jones, BA4, Sasha Bogdanovich, MD, PhD1 and Kiren Kresa-Reahl, MD1, (1)Atara Biotherapeutics, Thousand Oaks, CA, (2)University of Southern California, Los Angeles, CA, (3)Atara Biotherapeutics, South San Francisco, CA, (4)Adelphi Real World, Bollington, Cheshire, United Kingdom |
2023 | DMT27 | Poster | Disease-modifying therapy |
Effect of Longer-Term Ofatumumab Treatment on Disability Progression and Brain Volume Change |
Derrick S Robertson, MD, Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, Jeffrey A. Cohen, MD, Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, Stephen L. Hauser, MD, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, Ronald Zielman, MD, PhD, Novartis Pharma B.V., Amsterdam, Netherlands, Jing Xi, PhD, China Novartis Institutes For Biomedical Research Co., Ltd., Shanghai, China, Amin Azmon, PhD, Novartis Pharma A.G., Basel, Switzerland, Ayan Das Gupta, MSc, Novartis Healthcare Pvt. Ltd, Hyderabad, India, Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Heinz Wiendl, MD, Department of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital and University of Münster, Münster, Germany and Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland |
2023 | DMT28 | Poster | Disease-modifying therapy |
Acapella: Real-World Experience with Ocrelizumab, 6-Year Data |
Elizabeth A Douglas, MPH, Isabella O’Shea, B.S., Paige Greenawalt, B.S., Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
2023 | DMT29 | Poster | Disease-modifying therapy |
Real-World Safety of Dimethyl Fumarate and Fingolimod: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) |
Cortnee Roman, MSN, FNP-BC, Rocky Mountain MS Clinic, Salt Lake City, UT, Carrie M Hersh, DO, MS, FAAN, Mellen Program for Multiple Sclerosis Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, Timothy West, MD, Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, Stefan H Sillau, PhD, Neurology, Rocky Mountain MS center, aurora, CO and Enrique Alvarez, MD, PhD, MSCI, Department of Neurology, Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO |
2023 | DMT30 | Poster | Disease-modifying therapy |
An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients with Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial |
Evanthia Bernitsas, MD1, Anthony T Reder, MD2, Angel Chinea, MD3, Craig Herrman, MD4, Barbara C O’Brien, MD5, Richard A. Sater, MD, PhD6, Lilyana Amezcua, MD, MS7, Mitzi J Williams, MD8, Gregory F Wu, MD, PhD9, Timothy Vartanian, MD, PhD10, Jinglan Pei, PhD11, Juan Acosta, MD11 and Nancy L Monson, PhD12, (1)Wayne State University School of Medicine, Detroit, MI, (2)University of Chicago Medicine, Chicago, IL, (3)San Juan Bautista School of Medicine, Universidad Central del Caribe School of Medicine, Fundacion Eslerosis Multiple de PR, San Juan MS Center, Guaynabo, PR, Puerto Rico, (4)JWM Neurology, Indianapolis, IN, (5)Baptist Memorial Hospital-Collierville, Collierville, TN, (6)Cone Health Medical Group, Greensboro, NC, (7)Keck School of Medicine, University of Southern California, Los Angeles, CA, (8)Joi Life Wellness MS Center, Atlanta, GA, (9)Washington University in St. Louis, St. Louis, MO, (10)Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY, (11)Genentech, Inc., South San Francisco, CA, (12)University of Texas Southwestern Medical Center, Dallas, TX |
2023 | DMT31 | Poster | Disease-modifying therapy |
Acapella: Hypogammaglobulinemia in Ocrelizumab-Treated Patients, Year Six Data |
Isabella O’Shea, B.S., Elizabeth A Douglas, MPH, Paige Greenawalt, B.S., Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
2023 | DMT32 | Poster | Disease-modifying therapy |
Five-Year Safety of Ofatumumab in People Living with Relapsing Multiple Sclerosis |
Jeffrey A. Cohen, MD1, Stephen L. Hauser, MD2, Anne H. Cross, MD3, Kevin Winthrop, MD, MPH4, Heinz Wiendl, MD5, Jacqueline Nicholas, MD, MPH6, Sven G. Meuth, MD, PhD7, Paul S. Giacomini, MD8, Francesco Saccà, MD9, Ronald Zielman, MD, PhD10, Ayan Das Gupta, MSc11, Xixi Hu, PhD12, Roseanne Sullivan, PharmD12, Virginia DeLasHeras, MD13 and Ludwig Kappos, MD14, (1)Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, (2)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (3)Washington University School of Medicine, St. Louis, MO, (4)Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, (5)Department of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital and University of Münster, Münster, Germany, (6)OhioHealth Multiple Sclerosis Center, Columbus, OH, (7)Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, (8)Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (9)NSRO Department, University “Federico II” of Naples, Naples, Italy, (10)Novartis Pharma B.V., Amsterdam, Netherlands, (11)Novartis Healthcare Pvt. Ltd, Hyderabad, India, (12)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (13)Novartis Pharma AG, Basel, Switzerland, (14)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland |
2023 | DMT33 | Poster | Disease-modifying therapy |
Barriers and Potential Solutions for Advancing Inclusive Research in MS Clinical Studies |
Jacqueline Rosenthal, MD1, Lilyan Wright, PhD2, Jack Ratchford, PhD2, Alexandra Goodyear, PhD2 and Leorah Freeman, MD, PhD3, (1)Andrew C. Carlos Multiple Sclerosis Institute, Shepherd Center, Atlanta, GA, (2)Genentech, Inc., South San Francisco, CA, (3)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX |
2023 | DMT35 | Poster | Disease-modifying therapy |
The Impact of Proximity to Infusion/MS Clinic on Choice of Disease Modifying Therapy: Is Far Really Far? |
David Medvedev, Student1, Jill R Nelson, RN, BScN, MSCN1, Anna Kazimirchik, RN, MSCN1 and Galina Vorobeychik, MD, FRCPS(C), FAAN1,2, (1)Fraser Health Multiple Sclerosis Clinic, Burnaby, BC, Canada, (2)Neurology, University of British Columbia, Vancouver, BC, Canada |
2023 | DMT36 | Poster | Disease-modifying therapy |
Safety and Clinical Efficacy Outcomes from Long-Term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 2.5-Year Data |
Jiwon Oh, MD, PhD1, Sana Syed, MD, MPH2, Tong Li, PhD3, Naji Salloum, MD2, Timothy J. Turner, PhD2 and Robert J. Fox, MD4, (1)St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, (2)Sanofi, Cambridge, MA, (3)Sanofi, Bridgewater, NJ, (4)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH |
2023 | DMT37 | Poster | Disease-modifying therapy |
Early Clinical Experience with Cladribine Tablets in a Switching from High Efficacy Infusions |
Joash Lazarus, MD, Nancy Ross, PharmD, BCACP, MSCS, CSP and Collins Yates, RN, BSN, MSCN, Atlanta Neuroscience Institute, Atlanta, GA |
2023 | DMT38 | Poster | Disease-modifying therapy |
Baseline Cognition and MRI Measures of Patients with Relapsing Multiple Sclerosis in Enlighten: A Study of the Effect of Ozanimod on Cognitive Processing Speed |
John DeLuca, PhD1, Jon V. Riolo, MD2, Chun-Yen Cheng, MS2, Robert T. Naismith, MD3, Sibyl Wray, MD4, Ann Bass, MD5, Edward Fox, MD, PhD, FAAN6, Emily Riser, MD7, Burhan Chaudhry, MD2, Diego Silva, MD2 and Robert Zivadinov, MD, PhD8, (1)Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers – New Jersey Medical School, Newark, NJ, (2)Bristol Myers Squibb, Princeton, NJ, (3)Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO, (4)Hope Neurology MS Center, Knoxville, TN, (5)Neurology Center of San Antonio, San Antonio, TX, (6)Central Texas Neurology Consultants, Round Rock, TX, (7)Alabama Neurology Associates, Birmingham, AL, (8)Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY |
2023 | DMT39 | Poster | Disease-modifying therapy |
A Study of Practical Aspects of Transitioning to Oral Cladribine from S1P Modulators |
Julia A Bass, PharmD1, Michelle Maynard, PharmD, BCPS2, Staley Brod, MD3, Ahmed Z Obeidat, MD, PhD3 and Sam I Hooshmand, DO4, (1)Froedtert & the Medical College of Wisconsin, Milwaukee, WI, (2)Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI, (3)Neurology, Medical College of Wisconsin, Milwaukee, WI, (4)Department of Neurology, Medical College of Wisconsin, Milwaukee, WI |
2023 | DMT40 | Poster | Disease-modifying therapy |
Assessing the Value of Financial Assistance for Equitable Access to Specialty Medications in Adults with Multiple Sclerosis Using Health System Pharmacy Services |
Julie Wawrzyniak, PharmD, BCACP, MSCS1, Andrew Choma, PharmD, BCPS, BCGP1, Tiffany Otto, CPhT2 and Erin Collins, MS2, (1)University of Rochester Specialty Pharmacy, UR Medicine, Rochester, NY, (2)Neurology, UR Medicine, Rochester, NY |
2023 | DMT41 | Poster | Disease-modifying therapy |
Data and Outcomes Following Ofatumumab Premedication Protocol Updates |
Calli L Cook, DNP, FNP-C, FAANP1,2, Kiran Sayani, FNP-C1 and Julie J Patel, PharmD, BCACP1,3, (1)General Neurology, The Emory Clinic, Atlanta, GA, (2)Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, (3)Department of Pharmacy, Emory University Hospital Midtown, Atlanta, GA |
2023 | DMT42 | Poster | Disease-modifying therapy |
Beneficial Immunomodulatory & Anti-Inflammatory Effects of a.Pullulans N-163- B-Glucan in a Clinical Trial of Multiple Sclerosis Patients |
Samuel JK Abraham, MD, Ph.D1,2,3,4, Vidyasagar Devaprasad Dedeepiya, MD, DNB3, Chocanathan Vetrievel, MS5, Sudhakar Subramanian, MD6, Naoki Yamamoto, MD, Ph.D7, Nobunao Ikewaki, Ph.D8,9, Rajappa Senthilkumar, Ph.D2,3, Senthilkumar Preethy, BDS, M.Sc3, Koji Ichiyama, PhD10, Subramaniam Srinivasan, MD, FACP, FRCP(L)11 and Hiroto Kawashima, PhD12, (1)Centre for Advancing Clinical Research (CACR), University of Yamanashi, Chuo, Japan, (2)GN Corporation Co. Ltd, Kofu, Japan, (3)Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India, (4)Sophy Inc., Kochi, Japan, (5)BeWell Hospitals, Chennai, India, (6)Department of Anesthesia, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada, (7)National Center for Global Health and Medicine (NCGM), Chiba, Japan, (8)Kyushu University of Health and Welfare, Nobeoka, Japan, (9)Junsei Educational Institute, Nobeoka, Japan, (10)Antony-Xavier Inter-disciplinary Scholastics (AXIS), GN Corporation Co Ltd, Kofu, Yamanashi, Japan, (11)Mary- Yoshio Translational Hexagon (MYTH), Nichi-in Centre for Regerenative Medicine (NCRM), Chennai, TN, India, (12)Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan |
2023 | DMT43 | Poster | Disease-modifying therapy |
Ocrelizumab Use and Family Planning: NYU MS Center Experience |
Lana Zhovtis Ryerson, MD1,2, Dunia Gragui, .3, Francesca Chinea, BA4 and Eugene Toth, ba4, (1)Neurology, HMH JSUMC, Neptune, NJ, (2)Department of Neurology, NYU Langone Health, New York University, New York, NY, (3)Neurology, NYU Langone Health, New York, NY, (4)NYU, New York, NY |
2023 | DMT44 | Poster | Disease-modifying therapy |
Efficacy in Clinical and MRI Outcomes with Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS) |
Nicola De Stefano, MD, PhD1, Anat Achiron, MD, PhD2, Frederik Barkhof, MD, PhD3,4, Andrew Chan, MD5, Tobias Derfuss, MD6, Suzanne Hodgkinson, MBBS, PhD7, Letizia Leocani, MD, PhD8, Xavier Montalban, MD, PhD9, Alexandre Prat, MD, PhD10, Klaus Schmierer, MD, PhD11,12, Finn Sellebjerg, MD, PhD, DMSci13,14, Patrick Vermersch, MD, PhD15, Heinz Wiendl, MD16, Annette Lehn, PhD17, Andrzej Smyk, MD17 and Lidia Gardner, PhD18, (1)Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy, (2)Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel, (3)UCL Institute of Neurology, London, United Kingdom, (4)Department of Radiology, VU University Medical Center, Amsterdam, Netherlands, (5)Department of Neurology, , Bern University Hospital, University of Bern, Bern, Switzerland, (6)Department of Neurology, University Hospital Basel, Basel, Switzerland, (7)Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia, (8)Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy, (9)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain, (10)Department of Neurosciences, Université de Montréal, Montréal, QC, Canada, (11)The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom, (12)Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom, (13)Danish MS Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark, (14)Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, (15)Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, (16)Department of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital and University of Münster, Münster, Germany, (17)the healthcare business of Merck KGaA, Darmstadt, Germany, (18)EMD Serono Research and Development Institute, Inc., Billerica, MA |
2023 | DMT45 | Poster | Disease-modifying therapy |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analyses up to 9 Years in Patients with Relapsing and Primary Progressive Multiple Sclerosis |
Mark S Freedman, MSc MD1, Xavier Montalban, MD, PhD2, Timothy Vollmer, MD3, Jerry S Wolinsky, MD4, Regine Buffels, MD5, Cathy Chognot, PhD5, Nikki Jessop, MbChB, FCForPath5, Kalpesh Prajapati, MSc, M.Phil6 and Ludwig Kappos, PhD7, (1)Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada, (2)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, (3)Department of Neurology, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado Denver, Denver, CO, (4)Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)IQVIA Solutions Inc., Amsterdam, Netherlands, (7)Research Centre for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland |